BioSpace News Archive

Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced that the first healthy volunteers have been dosed in a Phase 1 clinical trial of its lead monoclonal antibody, DNTH103.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has entered into a research partnership with U.S. magnet solutions provider MagCorp to explore superconducting magnets for MR scanners that do not require cooling to ultra-low temperatures (-452 °F or -269 °C) using liquid helium.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place December 2-6 in Nashville, Tennessee.

Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a constituent stock in the MSCI Global Micro Cap Index (Hong Kong), with such inclusion to become effective after the U.S. market close today.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its financial results for the quarter ended Sept. 30, 2022, and provided a business update.

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, has recently come to the conclusion that PRP could become an effective chemosensitizer agent against pancreatic cancer.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting on December 1, 2022, at the Piper Sandler 34th Annual Healthcare Conference, held November 29-December 31, 2022, in New York City, New York.

Celularity, Inc., a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, shared that Chairperson, Founder and Chief Executive Officer Robert J. Hariri, M.D., Ph.D. addressed the Future Investment Initiative 6th Edition in Riyadh conference sponsored by the Future Investment Initiative at the plenary session: The Science and Technology for Extending Healthy Human Lifespan.

The University of Texas Medical Branch has been awarded a project agreement worth up to $87.4 million by the U.S. DOD’s JPEO-CBRND and the U.S. Department of HHS’ Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response, through the Medical CBRN Defense Consortium Other Transaction Authority, for the development of a vaccine technology against advanced and emerging viral threats.

Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) thanks Mr. Neim Malo, founder of Beefstro’s, for his ACP-01 testimonial interview now available on YouTube (https://youtu.be/1ezFC0oIU9s).